ZTS Q1 2024 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena

ZTSZoetis Inc.

$54B

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2.2B+9.5% YoY

Gross Profit

$1.5B68.9% margin

Operating Income

$801M36.6% margin

Net Income

$599M27.4% margin

EPS (Diluted)

$1.31

QoQ Revenue Growth

-1.0%

Cash Flow

Operating Cash Flow

$595M

Free Cash Flow

$455M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$14.3B

Total Liabilities

$9.3B

Stockholders' Equity

$5.1B

Cash & Equivalents

$2.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.2B	$2.0B	+9.5%
Gross Profit	$1.5B	$1.4B	+9.8%
Operating Income	$801M	$728M	+10.0%
Net Income	$599M	$552M	+8.5%

Revenue Segments

Dogs and Cats

$1.4B64%

Cattle

$391M18%

Poultry

$139M6%

Swine

$127M6%

Horses

$66M3%

Fish

$45M2%

Geographic Segments

United States Segment

$1.2B54%

International Segment

$1.0B46%